CSP exam test

CSP exam test PDC calculation - PDC = (# of unique days with supply / number of days in a period) x 100 Which medication is a Jak inhibitor? a. Humira (adalimumab) b. Orencia (abatacept) c. Actemra (toclizumab) d. Xeljanz (tofacitinib) - d. Xeljanz (tofacitinib) Which medication can elevate cholesterol? a. Actemra (toclizumab) b. Enbrel (etanercept) c. Simponi (golimumab) d. Kineret (anakinra) - a. Actemra (toclizumab) Which shingles vaccine is safe to administer with TNF inhibitors? a. Adacel b. Zostavax c. Shingrix d. Varivax - c. Shingrix Most biologics increase the risk of infections, which of the following also increases the risk of neutropenia? a. Rituxin (rituximab) b. Taltz (ixekizumab) c. Remicade (infliximab) d. Cimzia (certolizumab pegol) - b. Taltz (ixekizumab) Which psoriasis medication does not require screening for tuberculosis? a. Stelara (ustekinumab) b. Otezla (apremilast) c. Cocentyx (seculinumab) d. Humira (adalimumab) - b. Otezla (apremilast) What is the standard starting dose for Taltz (ixekizumab) when used to treat psoriatic arthritis? a. 160mg subcutaneously once, followed by 80mg subcutaneously at weeks 2, 4, 6, 8, 10 and 12; then 80mg subcutaneously every 4 weeks b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks c. 160mg subcutaneously once, followed by 80mg subcutaneously every week for 4 weeks, then 80mg every 4 weeks d. 160mg subcutaneously once, followed by 80mg subcutaneously every other week - b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks A 45 y/o, 200lb patient is struggling with severe dermatitis and the provider wants to potentially start a biologic. Which medication would you recommend? a. Protopic (tacrolimus) b. Humira (adalimumab) c. Stelara (ustekinumab) d. Dupixent (dupilumab) - d. Dupixent (dupilumab) A 56 y/o, 140lb patient with psoriasis will be starting Stelara (ustekinumab), but the provider wants to verify the dosing of the medication. What starting dose would you recommend? a. Inject 45 mg subcutaneously at weeks 0 and 4, followed by 45 mg every 12 weeks b. Inject 90 mg subcutaneously at weeks 0 and 4, followed by 90 mg every 12 weeks c. Infuse 260 mg IV over at least 1 hour as a single dose, followed